X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7398) 7398
Book Chapter (37) 37
Dissertation (4) 4
Book / eBook (3) 3
Conference Proceeding (2) 2
Publication (2) 2
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5103) 5103
index medicus (5095) 5095
animals (3020) 3020
bortezomib (2028) 2028
oncology (1933) 1933
proteins (1874) 1874
apoptosis (1809) 1809
proteasome endopeptidase complex - metabolism (1748) 1748
proteasome inhibitors (1693) 1693
cancer (1552) 1552
mice (1432) 1432
male (1394) 1394
proteasome (1301) 1301
cell biology (1289) 1289
ubiquitin (1287) 1287
female (1266) 1266
cell line, tumor (1185) 1185
antineoplastic agents - therapeutic use (1034) 1034
biochemistry & molecular biology (987) 987
multiple myeloma (950) 950
research (923) 923
proteasomes (903) 903
ubiquitin-proteasome system (862) 862
antineoplastic agents - pharmacology (829) 829
degradation (824) 824
expression (824) 824
hematology (819) 819
multiple myeloma - drug therapy (805) 805
apoptosis - drug effects (772) 772
gene expression (745) 745
multidisciplinary sciences (740) 740
nf-kappa-b (738) 738
signal transduction (726) 726
proteolysis (707) 707
research article (697) 697
activation (692) 692
health aspects (688) 688
kinases (681) 681
boronic acids - therapeutic use (673) 673
medicine (668) 668
pyrazines - therapeutic use (662) 662
pharmacology & pharmacy (654) 654
ubiquitination (644) 644
analysis (643) 643
middle aged (634) 634
care and treatment (633) 633
autophagy (622) 622
proteasome inhibitor (617) 617
ubiquitin - metabolism (589) 589
phosphorylation (579) 579
cell cycle (576) 576
science (567) 567
aged (562) 562
neurosciences (554) 554
biology (552) 552
oxidative stress (538) 538
physiological aspects (536) 536
chemotherapy (520) 520
proteasome inhibitors - therapeutic use (505) 505
mutation (504) 504
tumors (503) 503
antineoplastic combined chemotherapy protocols - therapeutic use (495) 495
proteasome inhibitors - pharmacology (492) 492
boronic acids - pharmacology (491) 491
inhibition (490) 490
genetic aspects (486) 486
multiple-myeloma (478) 478
pyrazines - pharmacology (478) 478
treatment outcome (474) 474
cells (469) 469
proteasome inhibitor bortezomib (461) 461
enzymes (460) 460
adult (456) 456
neoplasms - drug therapy (442) 442
rats (432) 432
therapy (417) 417
signal transduction - drug effects (413) 413
in-vitro (401) 401
biochemistry (400) 400
review (397) 397
drug therapy (388) 388
inhibitors (379) 379
protein (379) 379
rodents (376) 376
medicine, research & experimental (373) 373
cell proliferation - drug effects (372) 372
disease models, animal (367) 367
immunology (363) 363
pathway (356) 356
cells, cultured (353) 353
in-vivo (353) 353
protease inhibitors - therapeutic use (353) 353
cell line (352) 352
cell death (351) 351
disease (349) 349
proteasome inhibition (346) 346
cancer therapies (324) 324
cell proliferation (323) 323
proteasome endopeptidase complex (323) 323
inflammation (321) 321
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7389) 7389
Japanese (45) 45
French (17) 17
German (8) 8
Russian (6) 6
Polish (5) 5
Chinese (4) 4
Czech (3) 3
Hungarian (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Head & Neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment... 
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | SURGERY | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | ABL TYROSINE KINASE | PROTEASOME INHIBITION | CELL-CYCLE ARREST | VALPROIC ACID | DEPSIPEPTIDE FR901228 | PHASE-II TRIAL | OTORHINOLARYNGOLOGY | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2016, Volume 113, Issue 46, pp. 13162 - 13167
Journal Article
British journal of haematology, ISSN 0007-1048, 2017, Volume 179, Issue 2, pp. 198 - 218
Journal Article
Calcified tissue international, ISSN 1432-0827, 2017, Volume 102, Issue 2, pp. 227 - 250
Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve... 
Biochemistry, general | RANKL | c-Src inhibitors | Denosumab | DKK1 | Bisphosphonates | Cell Biology | Life Sciences | Radium 223 | Cathepsin k inhibitors | Bone metastasis | Orthopedics | mTOR inhibitors | Sclerostin | Romosozumab | Endocrinology | ADVANCED BREAST-CANCER | REFRACTORY MULTIPLE-MYELOMA | RANDOMIZED CONTROLLED-TRIAL | RENAL-CELL CARCINOMA | EVEROLIMUS PLUS EXEMESTANE | ZOLEDRONIC ACID | PHASE-II TRIAL | ENDOCRINOLOGY & METABOLISM | CATHEPSIN-K INHIBITOR | TYROSINE KINASE INHIBITOR | RESISTANT PROSTATE-CANCER | Humans | Bone Neoplasms - secondary | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Molecular Targeted Therapy | Proteasome Inhibitors - therapeutic use | Denosumab - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Bortezomib - therapeutic use | Androgen Antagonists - therapeutic use | Diphosphonates - therapeutic use | Bone Neoplasms - drug therapy | Cathepsin K - antagonists & inhibitors | Integrins - antagonists & inhibitors | Radiopharmaceuticals - therapeutic use | Medical research | Care and treatment | Mortality | Phosphonates | Cathepsins | Medicine, Experimental | Metastasis | Health aspects | Cancer | Bone diseases | Osteoblasts | Cancer therapies | Morbidity | Proteasome inhibitors | Quality of life | Metastases | Bone resorption | Bone growth | Bone cancer | Osteoclasts | Osteogenesis | Tumors
Journal Article